Administer subcutaneously (SC) or intravenously (IV). For SC administration, the patient or caregiver can be trained to inject. Administer daily until neutrophil count recovers or as directed by physician.

Filgrastim binds to G-CSF receptors on hematopoietic stem cells and progenitor cells, stimulating their proliferation, differentiation, and maturation into neutrophils. It also enhances the functional activity of mature neutrophils.

• •Hypersensitivity to filgrastim or any components of the product.
• •History of severe allergic reactions (e.g., anaphylaxis) to G-CSFs.

Store refrigerated between 2°C and 8°C (36°F and 46°F). Do not freeze. Protect from light. Do not shake.

Overdose effects are generally managed with supportive care. The effects are usually reversible upon discontinuation of therapy.

Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. It is unknown if filgrastim is excreted in human milk; caution should be exercised when administered to a nursing woman.